P33. Staged diabetes management: a complete disease state management

Ginsberg, Barry H.; Rs, Mazze

doi:10.1016/s0149-2918(96)80173-1

Cited by 6 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Health plans have responded in some cases with elaborate disease state management initiatives (16,17). Medical groups have begun using electronic medical records (18) and better information systems but are finding implementation issues difficult and costs worrisome.…”

Section: Pharmacy Datamentioning

confidence: 99%

Linking pharmacy and laboratory data to assess the appropriateness of care in patients with diabetes.

Wetzler

Snyder

2000

Diabetes Care

View full text Add to dashboard Cite

OBJECTIVE -To use pharmacy and laboratory data to assess diabetes care within a medical group and between medical groups and to determine dispensing patterns and the extent to which providers change therapy based on HbA 1c results.RESEARCH DESIGN AND METHODS -Participating groups submitted 1 year of data for continuously enrolled patients. Required data included date of birth, all diabetes-specific prescriptions (oral hypoglycemic agents and insulin), date of prescription, National Drug Code, all HbA 1c values, lower and upper normal limits, and date of testing.RESULTS -Few changes in therapy were noted despite the large percentages of patients with suboptimal control. Nearly 90% of the patients treated with medications received a monotherapy regimen involving one of three therapeutic agents: sulfonylureas, metformin, or insulin. More than three-fourths of the patients remained on the same therapy during the observation period despite the fact that 27% of these patients had HbA 1c values Ն8%. Nearly onefifth (18%) of patients had an HbA 1c level of Ն8% and no further testing for at least 90 days after the "actionable" HbA 1c result was obtained. Furthermore, 54% of patients with actionable HbA 1c results did not have a change in therapy initiated after the result was available.CONCLUSIONS -The American Diabetes Association recommendations to act on HbA 1c values Ն8% and to follow up regularly on patients found to be in suboptimal control do not appear to be applied in a consistent manner based on the pharmacy and laboratory data analyzed in this sample.

show abstract

Section: Pharmacy Datamentioning

confidence: 99%

Linking pharmacy and laboratory data to assess the appropriateness of care in patients with diabetes.

Wetzler

Snyder

2000

Diabetes Care

View full text Add to dashboard Cite

show abstract

“…The key feature of CADS is that it simplifies the work of the PCP by automatically integrating the essential factors necessary to make a recommendation for management -the patient's SMBG data from their uploads, current and previous medication, and current relevant laboratory data -and then making a recommendation based on established consensus algorithms (47).…”

Section: The Case For Systematic Rigorous Examination Of a Computer mentioning

confidence: 99%

Extension of a Computer Assisted Decision Support (CADS) Study to Improve Outcomes in Patients with Type 2 DM Treated by Primary Cary Providers (short title, CADS-X)

Vigersky¹

2012

View full text Add to dashboard Cite

“…Ginsberg et al 38 examines the effect of a disease state management system that emphasizes a care system for diabetics, primary care providers, and a team approach. No control group is involved, and the approach is one of treatment goals and time lines being set for success with individual therapies.…”

Section: Economic Analysismentioning

confidence: 99%

Use of Chromium Picolinate and Biotin in the Management of Type 2 Diabetes: An Economic Analysis

Fuhr

He²,

Goldfarb³

et al. 2005

Disease Management

View full text Add to dashboard Cite

P33. Staged diabetes management: a complete disease state management

Cited by 6 publications

References 0 publications

Linking pharmacy and laboratory data to assess the appropriateness of care in patients with diabetes.

Linking pharmacy and laboratory data to assess the appropriateness of care in patients with diabetes.

Extension of a Computer Assisted Decision Support (CADS) Study to Improve Outcomes in Patients with Type 2 DM Treated by Primary Cary Providers (short title, CADS-X)

Use of Chromium Picolinate and Biotin in the Management of Type 2 Diabetes: An Economic Analysis

Contact Info

Product

Resources

About